NEW YORK (GenomeWeb News) – Interleukin Genetics said today that it has signed up Labec Pharma of Madrid to distribute its genetic test for heart attack risk in Spain and Portugal.

The Cardio Health test identifies multiple genetic variations that can lead to overproduction of certain chemicals that can cause inflammation, and can indicate "a statistically significant risk" for heart attack, the Waltham, Mass.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.